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Abstract
Objectives. Incidence and risk factors of post-
transplant monoclonal gammopathy were studied
in renal transplant patients who received their
grafts between 1982 and 1992 (n = 390 grafts).
Immunoelectrophoresis was performed at annual inter-
vals after transplantation.
Results. Forty-six cases of clonal gammopathy were
detected: 35 monoclonal, 11 bi- or triclonal, with a
predominance of IgG and K light-chain subtypes (IgG,
39; IgA, 3; IgM, 4; K, 35; X, 19). Gammopathy was
transient in 17 patients (37%). The 5-year cumulative
incidence of gammopathy was 10.7%, much higher
than expected for a group of similar age from the
general population. Thirty of the 46 gammopathies
appeared within the first 2 years of transplantation.
Gammopathy never progressed to multiple myeloma
during follow-up (median 1 year; (range 0-10)); one
patient subsequently developed Kaposi sarcoma. The
2-year incidence of gammopathy was much higher in
patients transplanted in 1989-1991 (23/142) than in
1982-1988 (7/248) (P<0.000\). This coincided with
the use of quadruple induction immunosuppression
(cyclosporin A + azathioprine + prednisone plus either
ATG-Fresenius (ATG-F) or OKT3) since 1989. The
risk for acquiring gammopathy within 2 years of
transplantation was 14.7% (95% CI 9.2, 20.3%) in
patients receiving quadruple induction therapy, but
only 3.0% (CI 1.2, 6.1%) without such therapy
(/><0.0001). The risk for patients receiving quadruple
immunosuppression with OKT3 was 24.5%, signific-
antly greater than with ATG-F (11.8%, P<0.05).
Discriminant analysis revealed that the type of
immunosuppression, but not age or year of trans-
plantation, were independent risk factors for
gammopathy.
Conclusion. Monoclonal gammopathy frequently
occurs after renal transplantation. Risks are higher for
patients receiving quadruple induction immunosup-
pression, particularly if it includes OKT3. Follow-up
of these patients is warranted for the early detection
of malignant transformation.
Correspondence and offprint requests to: H. A. Bock MD, Division
of Nephrology, Kantonsspital, CH-4031 Basel, Switzerland.
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Introduction
Although monoclonal gammopathy has been fre-
quently observed after solid-organ and bone-marrow
transplantation, its incidence and spontaneous course
have not been well documented. Since a significant
proportion of patients with spontaneously occurring
gammopathy later develop multiple myeloma or other
lymphoproliferative syndromes [1], this disorder is
considered a potential premalignant state. However, it
is unknown whether the same holds true in the post-
transplant setting.
Transplantation-associated lymphoproliferative dis-
orders have become more common in recent years, a
finding that has been related the use of more power-
ful immunosuppressants. Recent data from the
Collaborative Transplant Study have demonstrated
that patients treated with antilymphocytic substances,
particularly OKT3, carry an increased risk for non-
Hodgkin lymphoma [2], and similar observations have
been made by others [3,4]. We became concerned when
we recently witnessed a sharp increase in the incidence
of monoclonal gammopathy in the kidney transplant
recipients of this centre.
We therefore decided to determine the incidence and
the clinical course of monoclonal gammopathy after
renal transplantation and to identify potential risk
factors. The Basel renal transplant population proved
uniquely suitable for this purpose, because annual
immunoelectrophoresis had routinely been carried out
in virtually all patients since 1982.
Subjects and methods
The charts of all patients transplanted in Basel between
1.1.1982 and 31.12.1991 were reviewed. During this period,
490 transplants were performed in 451 patients, and all
patients were regularly followed at our centre. During annual
check-up examinations, all patients underwent determination
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of standard renal and haematological parameters, a complete
history and physical examination, as well as a protein- and
immunoelectrophoresis. Immunoelectrophoresis was per-
formed using a Ready-System® immunoelectrophoresis
system. It was replaced by the more sensitive immunofixation
from March 1992*; the latter being carried out using a
Beckman® immunofixation kit using sample dilutions of 1:2
to 1:10, according to the manufacturer's specification.
We included in the present study all patients with a
minimum follow-up of 1 year after transplantation. The date
of last follow-up was 1 January 1994. Since the objective
was to determine the incidence of de-novo gammopathy,
patients with pre-existing gammopathy were excluded. Age
and the immunosuppressive regimen were considered the two
main potential risk factors.
During the time covered by the study, immunosuppression
was cyclosporin A (CsA) based. Initial immunosuppression
generally comprised CsA with or without prednisone (Pred)
in 1982-1984, CsA + Pred+ ATG-Fresenius (ATG-F) in
1985-1986, CsA + Pred+ azathioprine (Aza) in 1987-1988,
and CsA + Aza + Pred + either ATG-F or OK.T3 (quadruple
immunosuppression) from 1989 on [5]. We always attempted
to reduce immunosuppression to cyclosporin A monotherapy
within the first 3-5 months after transplantation unless
contraindicated on clinical grounds. Rejection episodes were
treated with pulse steroids and, if steroid resistant, with
antilymphocytic substances (i.e. ATG-Fresenius or OKT3)
from 1984-85 on.
Statistical calculations were carried out with the
'Statistica/w' software package on a personal computer
(Statsoft Co., Tulsa, Oklahoma, USA). Life-table analysis
was used to compute the cumulative incidence of gammopa-
thy. The Mann-Whitney U test was used for age comparison,
and the #2-test for the association of initial immunosuppres-
sive regimens with monoclonal gammopathy. Discriminant
analysis was used to identify risk factors contributing inde-
pendently to the occurrence of monoclonal gammopathy. A
P value <0.05 was considered significant.
Results
Based on the inclusion criteria, 390 of the 490 kidneys
were considered suitable for analysis. Of the 100
excluded grafts, 97 did not meet the minimum require-
ment of having at least one immunoelectrophoresis
> 1 year after transplantation: 55 of these because of
graft loss, 27 because of death within the first year,
and 15 because the appropriate analysis was not per-
formed or the patient was lost to follow-up. Three
were excluded because of pre-existing gammopathy.
Gammopathy was detected in 46 patients. Among
these, seven had received a living related donor kidney
and eight a second or third cadaveric graft. The
remaining 31 were first cadaveric graft recipients.
Of the 46 gammopathies, 35 were monoclonal and
11 bi- or triclonal. In most cases the amount of clonal
protein detected was low and not detectable by paper
protein electrophoresis. There was a predominance of
IgG and K light-chain phenotypes (Table 1).
Most of the patients developed gammopathy early
Table 1. Frequency
restriction
Gammopathies
IgG
IgA
IgM
and distribution
46
39
3
4
of isotype and
Monoclonal
Bi/triclonal
Kappa
Lambda
light-chain
35
11
35*
19*
*The sum of kappa plus lambda gammopathies exceeds 46 because
of the bi-and triclonal gammopathies.
after transplantation: it was detected at 1 year in 23
patients and within the first 2 years in 30 patients. The
median time from transplantation to gammopathy
detection was 1.5 years (range 1-8). As shown in
Figure 1, the cumulative incidence appeared to pro-
gressively flatten, giving a cumulative 5-year incidence
of 10.7%.
Gammopathy was transient in 17 of the 46 patients.
Of the remaining 29, gammopathy persisted to the end
of follow-up in 18. In 11 patients only one immunoelec-
trophoresis was available, and persistence could not
therefore be evaluated. The follow-up after detection
of gammopathy was very short (median 1 year (range
0-10)), reflecting the recent increase in de-novo gammo-
pathies (see below).
In no case was progression of gammopathy to non-
Hodgkin lymphoma or multiple myeloma observed.
One patient with persistent serum paraprotein later
developed Bence Jones proteinuria, and one patient
went on to develop Kaposi sarcoma. A third patient
with biclonal gammopathy was given a diagnosis of
presumptive multiple myeloma because of a dense
(30%) plasma cell infiltrate in the bone marrow aspir-
ate. However, as reported elsewhere [6], all signs of
disease regressed after reduction of immunosuppres-
sion, and the patient continues to do well. On 1.1.94,
40 of the 46 gammopathy patients were alive with a
functioning transplant, one had lost the graft from
Incidence of monoclonal gammopathy
* Although occasional samples were screened by immunofixation after
1987, every positive sample was confirmed by immunoelectrophoresis
to February 1992.
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Fig. 1. Cumulative incidence of monoclonal gammopathy after renal
transplantation (life table analysis).
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rejection and was back on haemodialysis, and five
patients had died, none of malignant disease.
The immunosuppressive regimens of the 46 patients
at the time of gammopathy detection did not differ
from non-gammopathy patients of the same time
period (data not shown). Similarly, immunosuppres-
sion at detection of gammopathy did not differ between
the 18 patients with persistent gammopathy (10 CsA
monotherapy, 8 dual or triple therapy) when compared
to the 17 patients with transient gammopathy (7 CsA
monotherapy, 10 dual or triple therapy).
There was a remarkable increase in the incidence of
de-no vo monoclonal gammopathies since 1989
(Figure 2). When limiting the analysis to gammopathy
within 2 years of transplantation (n = 30), gammopathy
was 5-6 times more common in patients transplanted in
1989-1991 (23/142) than in patients transplanted
between 1982 and 1988 (7/248) (P<0.0001). This
appeared to correlate with the initial immunosuppres-
sive regimen used. As shown in Table 2, the risk of
developing gammopathy was 3.0% for patients not
receiving any antilymphocytic substance and 3.1% for
patients treated with ATG-F as part of a triple induction
regimen (ATG-F + CsA+ Pred). However, patients
no. of grafts
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Fig. 2. Number of transplants according to different initial immuno-
suppression (D IS without ATG-F or OKT3, &ZM IS with ATG-F,
CsA and prednisone, H ATG quadruple, S3 OKT3 quadruple) and
monoclonal gammopathies ( • within 2 years of transplantation, O
after 2 years of transplantation).
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receiving quadruple induction immunosuppression had
a risk of 14.7% (P<0.0001 versus the other two groups).
Quadruple induction with ATG-F carried a risk of
10.4%, whereas the risk was 24.0% when OKT3 was
included in the regimen (P<0.05 OKT3 versus ATG-F).
Approximately one-half of the gammopathy cases in
each of the induction therapy groups were transient
and one-half persistent; the groups were not different
in this respect. The median age at transplantation of
patients who developed gammopathy (52.5 years (range
16-68)) was slightly higher than of patients without
gammopathy (49 years (9-70)); the difference was of
borderline significance (P=0.045).
Since age, the year of transplantation, and the
immunosuppressive regimen were all intercorrelated,
discriminant analysis was performed to identify inde-
pendent risk factors. The occurrence of gammopathy
within 2 years was used as the dependent variable, the
independent variables being age at transplantation, the
year of transplantation and the immunosuppressive
regimen: (1) no antilymphocytic substance, (2) ATG-F
induction with CsA-Pred, (3) ATG-F quadruple induc-
tion, or (4) OKT3 quadruple induction). Only the
immunosuppressive regimen (P< 10~5), but not age or
the year of transplantation proved to be an independ-
ent predictor. Thus, the increase of early gammopathies
in recent years was associated with the use of quadruple
immunosuppression, particularly if the latter included
OKT3.
To eliminate the potential bias caused by the intro-
duction of immunofixation in March 1992, the same
analysis was carried out in a subset of patients trans-
planted before November 1990 (333 patients, 15 gam-
mopathies, all diagnosed by immunoelectrophoresis).
Discriminant analysis again revealed only the immuno-
suppressive regimen (P<0.02), but not age or year of
transplantation as independent predictors. Of the 15
gammopathies, three had received ATG-F quadruple
induction and five had received OKT3 quadruple
induction, giving risks of 5.0% and 19.2% for the two
groups (Px0.09). Again, the gammopathy risk with
quadruple induction immunosuppression was signific-
antly greater than without (9.3% versus 2.8%,
P<0.05).
Discussion
The 10.7% incidence of monoclonal gammopathy at 5
years found in the present study makes gammopathy
Table 2. Gammopathies within 2 years of transplantation. Absolute risk according to immunosuppressive regimen
Initial immunosuppression MG no MG Risk
3.0%
3.1%
14.7%
10.4%
24.0%
95% confidence
interval
1.0-6.7
0.4-10.7
9.2-20.3
4.6-16.2
13.1-38.2
No induction
ATG triple induction
Quadruple induction
Quadruple ATG-F
Quadruple OKT3
5
2
23
11
12
164
63
133
95
38
MG = monoclonal gammopathy, ATG-triple = ATG-F + CsA+ Pred, Quadruple ATG-F = ATG-F + CsA + Aza + Pred, Quadruple OKT3 =
OKT3 + CyA + Aza + Pred.
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a common disorder after renal transplantation. There
is no doubt that this is much more than the prevalence
of monoclonal gammopathy in non-transplanted age-
matched controls. Data from the general population
show a 1% incidence of clonal gammopathy in cohorts
over 50 years of age, which increases to 3% in persons
over 70 [1,7]. The highest prevalence figures are
reported in the octogenarian nursing-home population
[8]. This entity, now termed 'monoclonal gammopathy
of unknown significance' (MGUS), is clearly a prema-
lignant condition of the elderly, and half of those
surviving long enough transform to a malignant state,
usually multiple myeloma, after a median follow-up of
19 years [1].
In contrast, the outcome of transplant-associated
gammopathy is still unclear. One carefully conducted
study with 3-month follow-up intervals reported a 23%
incidence of gammopathy within 2^ years after renal
transplantation, 80% of which were transient [9].
Gammopathy was more common in patients with
chronic rejection, and therefore with more intense
immunosuppression. A cross-sectional study reported
a 30% prevalence of gammopathy in renal transplant
patients [10]. Again, gammopathy was transient in 17
of 23 patients who were further followed, but two
patients developed myeloma. Age, but not the duration
of immunosuppression, appeared to favour gammopa-
thy occurrence. A third study, which reported a 12%
incidence at 8 years but with 85% appearing within 6
months of transplantation, reported age and the type
of immunosuppression to be risk factors: patients
treated with CsA + prednisone were at higher risk than
patients on Aza + prednisone or CsA + Aza + pred-
nisone [11]. Two patients developed multiple myeloma
and one a solitary plasmacytoma. Of note is the fact
that the myelomas appeared 10 and 13 years after
transplantation. Lastly, in a cross-sectional study of
110 renal transplant patients, monoclonal gammopathy
was detected in four, one of whom suffered from
myeloma [12].
Consistent with these reports, the course of gammo-
pathy in the present study was very variable: some
patients had transient gammopathy, while some main-
tained a steady, low level of paraprotein production.
Although no lymphoma or myeloma was found in the
46 patients of the present study, this should not lead
one to neglect the follow-up of these patients. One of
the patients developed Kaposi sarcoma, indicative of
a profound state of immunosuppression, and plasma-
cell proliferation in the bone marrow of an additional
patient was so pronounced that myeloma was strongly
suspected. Gammopathy was the first sign of Non-
Hodgkin lymphoma in a third patient, who was trans-
planted in 1981, just before the beginning of the
present study.
The recent bout of clonal gammopathy at our centre
(Figure 2) prompted us to evaluate the role of induc-
tion immunosuppression. By limiting the analysis to
patients with de-novo gammopathy within 2 years of
transplantation, we eliminated the bias of the longer
observation period in patients transplanted before
J. Passweg el al.
1989. The present analysis strongly suggests that the
quadruple immunosuppressive protocol used since
1989, which included CsA, azathioprine, steroids, and
either ATG-F or OKT3, favoured the development of
gammopathy. It remains open to debate whether the
critical factor is the overall intensity of immunosup-
pression or the addition of antilymphocytic globulins
(in particular, OKT3). Favouring the former possibil-
ity is the fact that triple induction immunosuppression
with ATG-F, CsA and steroids did not appear to
promote gammopathy (Table 2).
The change in the screening method for gammopathy
from immunoelectrophoresis to immunofixation in
March 1992 may be suspected to cause a methodologi-
cal bias. However, when the statistical analysis was
applied to a data subset where only immunoelectroph-
oresis was considered, results very similar to those in
the entire set were obtained. The only exception was
that due to the smaller patient number, the gammopa-
thy incidence between the ATG and OKT3 quadruple
groups no longer differed significantly. We therefore
considered it permissible to analyse the immunoelec-
trophoresis and immunofixation data together.
Gammopathy therefore appears to occur in circum-
stances similar to post-transplantation lymphoma. A
recent analysis of data from the Collaborative
Transplant Study demonstrated an increased risk for
non-Hodgkin lymphoma with CsA/azathioprine dual
therapy and a further increase with the use of anti-
lymphocytic globulins, particularly OKT3 [2]. Like the
gammopathies of the present study (Figure 1), most
of these lymphomas appeared early after transplanta-
tion. This may be a hint that post-transplantation
lymphoma and gammopathy have some similarities in
their pathogenesis.
The mechanisms leading to post-transplantation
gammopathy, however, are essentially speculative. One
hypothesis would propose that diminution of T-cell
mediated immune surveillance might temporarily allow
B-cell proliferation to escape, particularly if promoted
by viral infection. As a rule, control would later be
regained, resulting in stabilization or regression of the
expanded clones. However, if control remained sup-
pressed for a prolonged time period, progression to
lymphoma or myeloma might ensue. Alternatively, in
children with severe combined immunodeficiency
undergoing bone marrow transplantation, a particu-
larly high incidence of transient gammopathies has
been observed, leading to the hypothesis that recovery
of the immune system may be asynchronous [13,14].
Clones which recover faster than others then can cause
gammopathy, even though the overall system remains
controlled.
It should be emphasized that follow-up in the present
study is far too short to establish the dignity of this
syndrome. As illustrated by the literature cases [10],
transformation from gammopathy to myeloma usually
occurs late; it may take over a decade to develop.
Thus, the diagnosis of post-transplant gammopathy
has two potentially dangerous implications: early after
transplantation it may herald lymphoma and many
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years later, there may be transformation to multiple
myeloma.
In summary, monoclonal gammopathy occurs com-
monly after renal transplantation. Although it is fre-
quently transient, physicians should be aware that this
diagnosis carries an increased risk for lymphoma early
after transplantation and for myeloma many years
later. The present study demonstrates for the first time
an association of post-transplant monoclonal gammo-
pathy with immunosuppressive induction therapy,
namely a quadruple regimen which includes anti-
lymphocytic globulins.
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